Literature DB >> 2808210

Bactericidal activity of meropenem and interactions with other antibiotics.

A Ferrara1, G Grassi, F A Grassi, P D Piccioni, G Gialdroni Grassi.   

Abstract

MICs of meropenem for selected clinical isolates of bacteria were determined. Killing curves were performed on strains of methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staph. aureus (MRSA), methicillin-resistant Staph, epidermidis, Escherichia coli, Klebsiella spp., Enterobacter cloacae, Pseudomonas aeruginosa, Citrobacter freundii and Acinetobacter spp. A reduction of greater than or equal to 3 x log10 in viable cells was observed at 4 and 6 h of exposure to 4 and 8 x MIC, and this was usually maintained at 24 h (with a few exceptions for methicillin-resistant Staph, epidermidis and Ent. cloacae). At the MIC and twice the MIC regrowth tended to occur at 24 h although this varied from strain to strain. The interaction with other antibiotics was determined by the chequerboard technique. Usually an additive or synergistic effect was observed when meropenem or imipenem was used in combination with an aminoglycoside against Gram-negative species, while in a few cases antagonism occurred in combination with beta-lactams. Against Staph, aureus, MRSA and Staph, epidermidis synergism was usually obtained with combinations with teicoplanin or vancomycin and either synergism or addition with combinations with rifampicin, co-trimoxazole or ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808210     DOI: 10.1093/jac/24.suppl_a.239

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

2.  Evaluation of Aminoglycoside and Carbapenem Resistance in a Collection of Drug-Resistant Pseudomonas aeruginosa Clinical Isolates.

Authors:  Selina Y L Holbrook; Sylvie Garneau-Tsodikova
Journal:  Microb Drug Resist       Date:  2017-12-20       Impact factor: 3.431

3.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 4.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

5.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.